Aurinia Pharmaceuticals Backs New Lupus Nephritis Guidelines, Promoting LUPKYNIS's Importance

Aurinia Pharmaceuticals Endorses New Lupus Nephritis Guidelines, Highlighting LUPKYNIS's Role

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) expresses strong support for the American College of Rheumatology's (ACR) newly released 2024 guidelines on lupus nephritis (LN). These guidelines emphasize the critical need for effective treatment strategies that aim to preserve kidney function and prevent nephron loss, a concern that resonates deeply within the nephrology community. The ACR recommends a triple immunosuppression regimen for LN, underscoring the importance of innovative therapies like LUPKYNIS, which is suggested for use over a three to five-year period. Additionally, the guidelines advocate for a rapid tapering of steroid use to below 5 mg/day within the first six months of treatment, alongside a target of less than 0.5 g/g urine protein creatinine ratio within 12 months.

The ACR's recommendations are particularly significant given the results from the AURORA Clinical Program, especially the Phase 3 AURORA 1 study. This pivotal study demonstrates that patients treated with LUPKYNIS, in conjunction with mycophenolate mofetil (MMF) and low-dose glucocorticoids, show an 81% higher likelihood of achieving a complete renal response at the 52-week mark compared to those receiving MMF and low-dose glucocorticoids alone. Furthermore, over 80% of participants in the study successfully tapered their steroid dosage to below 2.5 mg/day by the 16-week point, establishing LUPKYNIS as the only therapy that meets the new guideline's steroid target based on randomized clinical trials. As the sole FDA-approved calcineurin inhibitor for the treatment of active LN, LUPKYNIS is positioned to be a cornerstone in the management of this complex condition across diverse patient demographics.

Dr. Greg Keenan, Chief Medical Officer at Aurinia, commends the ACR for the timely release of these guidelines, highlighting their potential to significantly improve the management of lupus nephritis. The guidelines not only call for innovative treatment approaches but also stress the importance of regular urine screening for proteinuria and recommend kidney biopsies as needed, showcasing a comprehensive approach to managing a condition that impacts many patients. This endorsement reinforces Aurinia's commitment to advancing care for individuals suffering from lupus nephritis, positioning LUPKYNIS as an essential component in the therapeutic landscape.

In addition to these developments, the ACR guidelines reflect a broader trend toward personalized medicine in rheumatology, emphasizing the need for tailored treatment plans based on individual patient responses. The integration of regular monitoring and proactive management strategies may lead to improved patient outcomes in the long term. This commitment to enhancing lupus nephritis treatment aligns with Aurinia's mission to provide innovative solutions for complex medical needs.